| Extracellular vesicle and particle biomarkers define multiple human cancers A Hoshino, HS Kim, L Bojmar, KE Gyan, M Cioffi, J Hernandez, ... Cell 182 (4), 1044-1061. e18, 2020 | 988 | 2020 |
| Epigenomic alterations define lethal CIMP-positive ependymomas of infancy SC Mack, H Witt, RM Piro, L Gu, S Zuyderduyn, AM Stütz, X Wang, ... Nature 506 (7489), 445-450, 2014 | 671 | 2014 |
| Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma H Witt, SC Mack, M Ryzhova, S Bender, M Sill, R Isserlin, A Benner, ... Cancer cell 20 (2), 143-157, 2011 | 583 | 2011 |
| Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial JR Park, SG Kreissman, WB London, A Naranjo, SL Cohn, MD Hogarty, ... Jama 322 (8), 746-755, 2019 | 307 | 2019 |
| Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors EM Fiala, G Jayakumaran, A Mauguen, JA Kennedy, N Bouvier, Y Kemel, ... Nature cancer 2 (3), 357-365, 2021 | 126 | 2021 |
| Humanized 3F8 anti-GD2 monoclonal antibody dosing with granulocyte-macrophage colony-stimulating factor in patients with resistant neuroblastoma: a phase 1 clinical trial BH Kushner, IY Cheung, S Modak, EM Basu, SS Roberts, NK Cheung JAMA oncology 4 (12), 1729-1735, 2018 | 105 | 2018 |
| Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study S Modak, JB Le Luduec, IY Cheung, DA Goldman, I Ostrovnaya, ... Oncoimmunology 7 (8), e1461305, 2018 | 84 | 2018 |
| Survival impact of anti-GD2 antibody response in a phase II ganglioside vaccine trial among patients with high-risk neuroblastoma with prior disease progression IY Cheung, NKV Cheung, S Modak, A Mauguen, Y Feng, E Basu, ... Journal of Clinical Oncology 39 (3), 215-226, 2021 | 82 | 2021 |
| Immunotherapy of childhood sarcomas SS Roberts, AJ Chou, NKV Cheung Frontiers in oncology 5, 181, 2015 | 82 | 2015 |
| ATRX in-frame fusion neuroblastoma is sensitive to EZH2 inhibition via modulation of neuronal gene signatures ZA Qadeer, D Valle-Garcia, D Hasson, Z Sun, A Cook, C Nguyen, ... Cancer Cell 36 (5), 512-527. e9, 2019 | 76 | 2019 |
| COVID‐19 disease in New York City pediatric hematology and oncology patients B Gampel, AGT Lucas, L Broglie, RD Gartrell‐Corrado, MT Lee, J Levine, ... Pediatric blood & cancer 67 (9), 2020 | 70 | 2020 |
| Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin BH Kushner, I Ostrovnaya, IY Cheung, D Kuk, S Modak, K Kramer, ... Oncotarget 7 (4), 4155, 2015 | 64 | 2015 |
| Successful Targeted Therapy of Refractory Pediatric ETV6-NTRK3 Fusion-Positive Secretory Breast Carcinoma N Shukla, SS Roberts, MO Baki, Q Mushtaq, PE Goss, BH Park, ... JCO precision oncology 1, 1-8, 2017 | 63 | 2017 |
| Characterization of on-target adverse events caused by TRK inhibitor therapy D Liu, J Flory, A Lin, M Offin, CJ Falcon, YR Murciano-Goroff, E Rosen, ... Annals of Oncology 31 (9), 1207-1215, 2020 | 62 | 2020 |
| Immunotherapeutic targeting of GPC3 in pediatric solid embryonal tumors MV Ortiz, SS Roberts, J Glade Bender, N Shukla, LH Wexler Frontiers in oncology 9, 108, 2019 | 58 | 2019 |
| Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high‐dose salvage regimen and review of the literature BH Kushner, S Modak, K Kramer, EM Basu, SS Roberts, NKV Cheung Cancer 119 (3), 665-671, 2013 | 56 | 2013 |
| Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: results of a phase II study S Modak, BH Kushner, E Basu, SS Roberts, NKV Cheung Pediatric blood & cancer 64 (8), e26448, 2017 | 54 | 2017 |
| GABAergic system gene expression predicts clinical outcome in patients with neuroblastoma SS Roberts, M Mori, P Pattee, J Lapidus, R Mathews, JP O'Malley, ... Journal of clinical oncology 22 (20), 4127-4134, 2004 | 54 | 2004 |
| A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: L ong‐term progression‐free survival of patients with resistant neuroblastoma BH Kushner, NKV Cheung, S Modak, OJ Becher, EM Basu, SS Roberts, ... International journal of cancer 140 (2), 480-484, 2017 | 53 | 2017 |
| Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers N Shukla, MF Levine, G Gundem, D Domenico, B Spitzer, N Bouvier, ... Nature communications 13 (1), 2485, 2022 | 52 | 2022 |
